Genomtec (GMT) Investor Update summary

Management and organizational changes

• International team of 20 experts based in Wrocław and Kent, UK, led by co-founder Miron Tokarsky, with expertise in molecular biology, finance, and photonics.

• Restructuring aligns with the M&A process, separating Genomtec ID, OncoSNAAT, and food safety projects into dedicated subsidiaries to support transactions and increase value.

M&A strategy

• Process ongoing since July 2023, with dozens of meetings, signed NDAs, and information exchanged with interested parties across five key areas.

• Clairfield Partners is advising on strategic partnerships, licensing, or full or partial sales of IP and technology, including buyer outreach, due diligence, and negotiations.

• Genomtec ID is to be separated into a dedicated entity for a potential sale; the intended plan is to sell 100% of its shares and distribute net proceeds to investors through dividends or share buybacks. A similar approach is intended for OncoSNAAT when technologically ready.

• Strategic options remain under review, and planned actions may change based on legal analyses and partner negotiations.

• Growing partner interest has prompted consideration of selling OncoSNAAT separately; plans include expanding its team and engaging an international advisor.

Technology and product development

• Focus on point-of-care genetic diagnostics using proprietary SNAAT and LAMP isothermal amplification technologies.

• LAMP enables rapid, specific DNA/RNA detection at femtogram levels in under 30 minutes, with high resistance to sample inhibitors.

• Genomtec ID supports multiplexed, mobile, low-cost diagnostics; work continues on heating-system stability and faster testing, with stability confirmed and amplification times reduced.

• Production costs for cards and reagents fell by over 70%; process optimization reduced reagent costs by up to 80%.